Latest News

Embracing Growth, Celebrating a New Chapter | Singapore and Emerging Markets Pharmaceutical Development Forum Successfully Held
2025-07-18

Embracing Growth, Celebrating a New Chapter | Singapore and Emerging Markets Pharmaceutical Development Forum Successfully Held

On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited (“CMS” or the “Group”) on the Main Board of the Singapore Exchange (“SGX”), SGX and CMS co-hosted the “Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner”. Held in a grand fashion, the event was held at the Group’s CDMO manufacturing facility, PharmaGend, which is located in Tuas, Singapore.   The event brought together about 150 representatives from local government agencies, multinational pharmaceutical companies, innovative biotech companies, leading investment institutions, and the KOLs in the pharmaceutical industry. Through a series of insightful keynote speeches and panel discussions, guests engaged in in-depth exchanges and shared ideas on various topics, such as the pharmaceutical industry’s development in Singapore and emerging markets across the Asia-Pacific region, the breakthroughs and overseas expansion of Chinese innovative drugs, the globalization strategies, commercialization pathways, as well as ecosystem collaboration of innovative pharmaceutical companies.   The forum began […]

Learn More
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today
2025-07-15

A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today

On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).     Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.   At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast […]

Learn More
IND Approval: CMS’s Self-developed Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Atopic Dermatitis Indication
2025-07-14

IND Approval: CMS’s Self-developed Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Atopic Dermatitis Indication

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that innovative drug CMS-D001 tablets (“CMS-D001”) self-developed by its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) together with its subsidiaries, has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 July 2025. The NMPA grants the consent to conduct a clinical trial evaluating the safety and efficacy of CMS-D001 for the treatment of atopic dermatitis (AD).   CMS-D001 CMS-D001 is a highly selective TYK2 (tyrosine kinase 2) inhibitor. TYK2 is a member of the JAK kinase family, which is an important component in immune cell […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News